Review sharpens focus on pimobendan dosing in cats
Bottom line
Pimobendan remains an off-label option in cats, but a new review in Veterinary Medicine International underscores that feline dosing is still being extrapolated from limited studies rather than a robust, cat-specific evidence base. Across the available literature, the most commonly used regimen appears to be about 0.25 mg/kg by mouth every 12 hours, often operationalized in practice as 0.625 mg to 1.25 mg per cat every 12 hours, particularly in cats with congestive heart failure or other cardiomyopathies without clinically important outflow tract obstruction. The review’s central point is that species differences matter: cats can reach higher plasma concentrations than dogs, which is why the long-standing habit of borrowing canine dosing continues to draw scrutiny. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is a reminder that pimobendan use in cats is still guided by low-level evidence, cardiology consensus, and clinician experience more than definitive dose-finding trials. The ACVIM feline cardiomyopathy consensus says pimobendan can be considered in cats without clinically relevant left ventricular outflow tract obstruction, and lists a commonly used dosage of 0.625 to 1.25 mg per cat every 12 hours by mouth. More recent evidence reviews similarly describe 1.25 mg every 12 hours, or roughly 0.25 mg/kg every 12 hours, as the most clinically used approach, while also cautioning that dose escalation above that level should be monitored closely. (pmc.ncbi.nlm.nih.gov)
What to watch: The next step is better feline-specific pharmacokinetic, safety, and outcomes data, especially in cats with hypertrophic cardiomyopathy, congestive heart failure, or dynamic outflow tract obstruction. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Drug
- Pimobendan
- Species
- Cats
- Use status
- Off-label in cats
- Most commonly used oral dose
- About 0.25 mg/kg every 12 hours
- Common practical dose range
- 0.625 mg to 1.25 mg per cat every 12 hours
- ACVIM consensus
- Can be considered in cats without clinically relevant left ventricular outflow tract obstruction
- Evidence base
- Dose is extrapolated from limited studies, not robust cat-specific dose-finding trials
- Pharmacology concern
- Cats can reach higher plasma concentrations than dogs
A new review focused on pimobendan dosing in domestic cats adds weight to a familiar clinical reality: the drug is widely used in feline cardiology, but the dosing evidence remains thin and still leans heavily on canine-derived practice patterns. The available literature points to a practical standard of about 0.25 mg/kg orally every 12 hours, often rounded to 0.625 mg to 1.25 mg per cat every 12 hours, even though pimobendan is not licensed for cats and species-specific pharmacokinetic differences complicate direct extrapolation from dogs. (pubmed.ncbi.nlm.nih.gov)
That question has been hanging over feline cardiology for years. Pimobendan has recognized value in dogs with heart failure, but its role in cats has been less straightforward because many feline patients have hypertrophic cardiomyopathy rather than primary systolic failure, and clinicians have long worried that positive inotropy could worsen dynamic left ventricular outflow tract obstruction in some cats. The 2020 ACVIM consensus on feline cardiomyopathies reflected that uncertainty, stating that pimobendan can be considered in cats without clinically relevant LVOTO and citing 0.625 mg to 1.25 mg per cat every 12 hours by mouth as a commonly used dosage. (pmc.ncbi.nlm.nih.gov)
More recent reviews and primary studies help explain why that dose has persisted. A 2025 practical evidence-based review in the Journal of Feline Medicine and Surgery concluded that 0.25 mg/kg every 12 hours is generally well tolerated in cats and said 1.25 mg every 12 hours has become the most clinically utilized dose, with minimal to no adverse effects attributed to that scheme in the published literature. Experimental and pharmacodynamic studies in healthy cats and cats with subclinical hypertrophic cardiomyopathy have used doses ranging from 0.125 mg/kg to 0.5 mg/kg every 12 hours, but the authors caution that higher doses deserve close monitoring until rhythm, rate, and long-term safety questions are better answered. (pubmed.ncbi.nlm.nih.gov)
The underlying concern is pharmacology, not just habit. Earlier work found that after a single oral dose, cats achieved plasma concentrations substantially higher than those reported in dogs, reinforcing the possibility that feline patients may not handle canine-style assumptions cleanly. That concern is one reason recent reviewers have emphasized that current dosing is based less on formal feline dose-optimization studies and more on accumulated clinical use, small pharmacodynamic studies, retrospective series, and expert opinion. (pmc.ncbi.nlm.nih.gov)
Industry and expert commentary remains measured rather than enthusiastic. A University of Illinois cardiology update noted that prospective evidence has not shown a survival benefit in cats with congestive heart failure secondary to hypertrophic cardiomyopathy, even as retrospective studies and clinical experience suggest the drug may help selected feline patients. Merck Veterinary Manual takes a similarly cautious line, saying routine use in cats is probably not warranted based on current evidence, but that pimobendan may be tried when a cat is no longer responding to conventional heart failure therapy. (vetmed.illinois.edu)
Why it matters: For general practitioners and cardiologists, the practical takeaway is that pimobendan dosing in cats is converging around a de facto standard, but not because the evidence is settled. In cats with congestive heart failure, global systolic dysfunction, or selected cardiomyopathies without clinically relevant obstruction, 0.625 mg to 1.25 mg per cat every 12 hours remains the most defensible starting point in the literature. But the review also highlights the need to individualize therapy, especially in smaller cats, cats with suspected LVOTO, and patients receiving multidrug heart failure protocols. For conversations with pet parents, this is also a useful reminder that feline use is off-label and that expectations should be framed around limited evidence, close monitoring, and case selection. (pmc.ncbi.nlm.nih.gov)
What to watch: Expect continued attention to feline-specific dose optimization, especially prospective studies that compare outcomes by phenotype, obstruction status, and dose band. The biggest gap is still not whether pimobendan is used in cats, but which cats benefit most, at what dose, and with what safety tradeoffs over time. (pubmed.ncbi.nlm.nih.gov)